Gefitinib-induced interstitial lung disease showing improvement after cessation: Disassociation of serum markers

Respirology

Volumn 11, Issue 2, 2006, Pages 217-220

  Kitajima, Hiroko ^a   Takahashi, Hiroki ^a   Harada, Kazutoki ^a   Kanai, Akiko ^a   Inomata, Shin Ichiro ^a   Taniguchi, Haruko ^a   Saikai, Toyohiro ^a   Abe, Shosaku ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gefitinib; Interstitial lung disease; KL 6; Lung cancer; Surfactant protein A; Surfactant protein D

Indexed keywords

BIOLOGICAL MARKER; GEFITINIB; PROTEIN; PROTEIN KL 6; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); DISEASE MARKER; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LOEFFLER PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SERUM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MIDDLE AGED; MUCINS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; QUINAZOLINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33644823055     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.00835.x     Document Type: Article

References (23)

1. Sirotnak FM Zakowski MF Miller VA Scher HI Kris MG Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase ClinCancer Res 2000 6 4885 92
2. Ciardiello F Caputo R Bianco R et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor ClinCancer Res 2001 7 1459 65
3. MDSI. Pharmaceuticals and Medical Devices Safety Information No188Review of Gefitinib (in Japanese). Apr 2003 [Cited 25 Jul 2003.] Available from URL:
4. Inoue A Saijo Y Maemondo M et al. Severe acute interstitial pneumonia and gefitinib Lancet 2003 361 137 9
5. Okamoto I Fijii K Matsumoto M et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer Lung Cancer 2003 40 339 42
6. Rabinowits G Herchenhorn D Rabinowits M Weatge D Torres W Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine Anticancer Drugs 2003 14 665 8
7. Kuroki Y Tsutahara S Shijubo N et al. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis AmRevRespirDis 1993 147 723 9
8. Nagae H Takahashi H Kuroki Y et al. Enzyme-linked immunosorbent assay using F(ab′)2 fragment for the detection of human pulmonary surfactant protein D in sera ClinChimActa 1997 266 157 71
9. Kohno N Akiyama M Kyoizumi S Hakoda M Kobuke K Yamakido M Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma JpnJClinOncol 1988 18 203 16
10. Kohno N Awaya Y Oyama T et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease AmRevRespir Dis 1993 148 637 42
11. Kuroki Y Fukada Y Takahashi H Akino T Monoclonal antibodies against human pulmonary surfactant apoproteins: specificity and application in immunoassay BiochimBiophysActa 1985 836 201 9
12. Mizutani Y Nakajima T Morinaga S et al. Immunohistochemical localization of pulmonary surfactant apoproteins in various lung tumors. Special reference to nonmucus producing lung adenocarcinomas Cancer 1988 61 532 7
13. Naranjo CA Busto U Sellers EM et al. A method for estimating the probability of adverse drug reactions ClinPharmacolTher 1981 30 239 45
14. Cooper JA Jr White DA Matthay RA Drug-induced pulmonary disease. Part 1: cytotoxic drugs AmRevRespirDis 1986 133 321 40
15. Cooper JA Jr White DA Matthay RA Drug-induced pulmonary disease. Part 2: noncytotoxic drugs AmRevRespirDis 1986 133 488 505
16. Webb WR Muller NL Naidich DP Diseases characterized primarily by linear and reticular opacities In Webb WR Muller NL Naidich DP (eds). High-Resolution CT of the Lung 3rd edn Lippincott Williams and Wilkins Philadelphia 2001 193 257
17. Inomata S Takahashi H Nagata M et al. Acute lung injury as an adverse event of gefitinib Anti-cancer Drugs 2004 15 461 7
18. Takahashi H Fujishima T Koba H et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent AmJRespirCritCare Med 2000 162 1109 14
19. Takahashi H Kuroki Y Tanaka H et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis AmJRespirCritCare Med 2000 162 258 63
20. Ohnishi H Yokoyama A Kondo K et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases AmJRespirCritCare Med 2002 165 378 81
21. Ohnishi H Yokoyama A Yasuhara Y et al. Circulating KL-6 levels in patients with drug induced pneumonitis Thorax 2003 58 872 5
22. Fujii M Tanaka H Kameda M et al. Elevated serum surfactant protein A and D in a case of acute eosinophilic pneumonia InternMed 2004 43 423 6
23. Doyle IR Bersten AD Nicholas TE Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure AmJRespirCritCare Med 1997 156 1217 29